HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in ISI Web of Science Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via ISI Web of Science (1) Citing Articles via Google Scholar Google Scholar Articles by Sze, L. Articles by Brändle, M. Search for Related Content PubMed PubMed Citation Articles by Sze, L. Articles by Brändle, M.

Effect of transsphenoidal surgery on sleep apnoea in acromegaly

Division of Endocrinology and Diabetes, Department of Internal Medicine, Kantonsspital St Gallen, 9007 St Gallen, Switzerland, ¹ Division of Endocrinology and Diabetes, Department of Internal Medicine, University Hospital of Zürich, 8091 Zürich, Switzerland, ² Division of Pneumology, Department of Internal Medicine, University Hospital of Zürich, 8091 Zürich, Switzerland and ³ Department of Neurosurgery, University Hospital of Zürich, 8091 Zürich, Switzerland

(Correspondence should be addressed to L Sze; Email: lisa.sze{at}bluewin.ch)

Objective: Sleep apnoea syndrome (SAS) is common in acromegaly and both diseases are independently associated with hypertension and insulin resistance contributing to increased morbidity and mortality. Pituitary surgery remains the principal treatment modality in acromegaly. The aim of this study was to assess the prevalence and risk factors of SAS in acromegaly and to analyze the effect of transsphenoidal adenomectomy on SAS and cardiovascular risk factors.

Subjects and methods: Thirteen consecutive patients (seven women and six men, aged 25–77 years) with newly diagnosed acromegaly were prospectively studied. Biochemical assessment (IGF-I, GH, acid labile subunit, fasting blood glucose (FBG), insulin), overnight respiratory polygraphy, and an Epworth Sleepiness scale score (ESS) were obtained before and 12 weeks after surgery. SAS was defined by an ESS 10 and 5 apnoeas/hypopnoeas (central or obstructive) per hour.

Results: Six of the thirteen (46%) patients had SAS. Risk factors were male gender (83.3 vs 14.3% without SAS) and long disease duration until diagnosis of acromegaly (10.2 ± 3.2 vs 4.6 ± 3.6 years, mean ± S.D.). Ten patients had a homeostasis assessment model score 4 indicating insulin resistance and one had diabetes mellitus requiring insulin. Seven patients had hypertension ( 140/90 mmHg). Postoperatively, GH and IGF-I levels decreased, but only five patients were cured. However, SAS resolved in all patients irrespective of whether acromegaly was cured or not. FBG (5.5 ± 1.2 vs 4.8 ± 0.4 mmol/l) and systolic blood pressure (150.8 ± 18.5 vs 130.8 ± 17.5 mmHg) decreased in all SAS patients.

Conclusion: We found a high prevalence of SAS in acromegaly patients, in particular, in men and those with long duration of disease. Importantly, a marked reduction of GH excess by transsphenoidal adenomectomy may cure SAS and improve insulin resistance and hypertension.

This article has been cited by other articles:

				M. P Matta, E. Couture, L. Cazals, D. Vezzosi, A. Bennet, and P. Caron Impaired quality of life of patients with acromegaly: control of GH/IGF-I excess improves psychological subscale appearance Eur. J. Endocrinol., March 1, 2008; 158(3): 305 - 310. [Abstract] [Full Text] [PDF]

				A. A. van der Klaauw, O. M. Dekkers, A. M. Pereira, K. W. van Kralingen, and J. A. Romijn Increased Daytime Somnolence despite Normal Sleep Patterns in Patients Treated for Nonfunctioning Pituitary Macroadenoma J. Clin. Endocrinol. Metab., October 1, 2007; 92(10): 3898 - 3903. [Abstract] [Full Text] [PDF]